Connect with us

Technology

Nuvei Files an Amendment to Schedule 13E-3

Published

on

MONTREAL, June 7, 2024 /PRNewswire/ — Nuvei Corporation (“Nuvei” or the “Company”) (Nasdaq: NVEI) (TSX: NVEI), announced today that it has filed a second amendment to its previously filed Rule 13e-3 transaction statement on Schedule 13E-3 (the “Schedule 13E-3”) originally filed with the U.S. Securities and Exchange Commission (“SEC”) on May 14, 2024, as supplemented by an amendment previously filed by the Company with the SEC on June 4, 2024. Both amendments to the Schedule 13E-3 are available without charge on Nuvei’s profile on EDGAR at www.sec.gov, and on its SEDAR+ profile at www.sedarplus.ca.

No changes have been made to the terms or conditions of the previously announced going private transaction with Advent International (the “Transaction”), or the date of the special meeting of shareholders of Nuvei called to approve the Transaction. Shareholders are encouraged to vote “FOR” the special resolution approving the Transaction in advance of the June 14, 2024 at 10:00 a.m. (Eastern time) deadline.

No Offer of Solicitation 

This announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell Subordinate Voting Shares of Nuvei.

The full details of the Transaction are described in the management information circular (including the related letter of transmittal and all other offer documents filed by Nuvei with the SEC), which is available without charge on the SEC’s website at www.sec.gov or on Nuvei’s investor relations website at investors.nuvei.com. Offer documents required to be filed in Canada are also available without charge at www.sedarplus.ca. INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE SCHEDULE 13E-3 AND OTHER MATERIALS FILED WITH THE SEC, AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE CORPORATION, THE TRANSACTION, AND RELATED MATTERS.

About Nuvei

Nuvei (Nasdaq: NVEI) (TSX: NVEI) is the Canadian fintech company accelerating the business of clients around the world. Nuvei’s modular, flexible and scalable technology allows leading companies to accept next-gen payments, offer all payout options and benefit from card issuing, banking, risk and fraud management services. Connecting businesses to their customers in more than 200 markets, with local acquiring in 50 markets, 150 currencies and 700 alternative payment methods, Nuvei provides the technology and insights for customers and partners to succeed locally and globally with one integration.

Forward-Looking Information

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “Forward-looking information”) within the meaning of applicable securities laws. This forward-looking information is identified by the use of terms and phrases such as “may”, “would”, “should”, “could”, “expect”, “intend”, “estimate”, “anticipate”, “plan”, “foresee”, “believe”, or “continue”, the negative of these terms and similar terminology, including references to assumptions, although not all forward-looking information contains these terms and phrases. Particularly, statements regarding the proposed transaction, including the proposed timing and various steps contemplated in respect of the transaction, are forward-looking information.

In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

Forward-looking information is based on management’s beliefs and assumptions and on information currently available to management, and although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, investors are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information.

Forward-looking information involves known and unknown risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, the risk factors described in greater detail under “Risk Factors” of the Company’s annual information form filed on March 5, 2024. These risks and uncertainties further include (but are not limited to) as concerns the transaction, the failure of the parties to obtain the necessary shareholder, regulatory and court approvals or to otherwise satisfy the conditions to the completion of the transaction, failure of the parties to obtain such approvals or satisfy such conditions in a timely manner, significant transaction costs or unknown liabilities, failure to realize the expected benefits of the transaction, and general economic conditions. Failure to obtain the necessary shareholder, regulatory and court approvals, or the failure of the parties to otherwise satisfy the conditions to the completion of the transaction or to complete the transaction, may result in the transaction not being completed on the proposed terms, or at all. In addition, if the transaction is not completed, and the Company continues as a publicly-traded entity, there are risks that the announcement of the proposed transaction and the dedication of substantial resources of the Company to the completion of the transaction could have an impact on its business and strategic relationships (including with future and prospective employees, customers, suppliers and partners), operating results and activities in general, and could have a material adverse effect on its current and future operations, financial condition and prospects. Furthermore, in certain circumstances, the Company may be required to pay a termination fee pursuant to the terms of the arrangement agreement entered into in connection with the Transaction which could have a material adverse effect on its financial position and results of operations and its ability to fund growth prospects and current operations.

Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein represents our expectations as of the date hereof or as of the date it is otherwise stated to be made, as applicable, and is subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

For further information, please contact:
Investors
Kingsdale Advisors
contactus@kingsdaleadvisors.com

Chris Mammone, Head of Investor Relations
IR@nuvei.com

Media
Joel Shaffer
FGS Longview
Joel.shaffer@fgslongview.com

NVEI-IR

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvei-files-an-amendment-to-schedule-13e-3-302167192.html

SOURCE Nuvei

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Immorta Bio to Present New Data on SenoVax™ and StemCell Revivify™ at Biotech Showcase 2025

Published

on

By

Senolytic Immunotherapy and Cellular Rejuvenation platforms are progressing toward clinical development

MIAMI, Jan. 10, 2025 /PRNewswire/ — Immorta Bio Inc., a leader in longevity-focused biotechnologies, announced today that it will present its latest developments at the upcoming Biotech Showcase in San Francisco, CA. The company’s presentation will provide insights into its groundbreaking research and technological advancements aimed at Treating Diseases of Aging and Treating Aging as Disease™.

Details of the presentation are as follows:

Event: Biotech Showcase 2025
Date: January 14, 2025
Time: 4 PM Pacific
Location: Franciscan C, Ballroom Level

Immorta Bio’s innovative platform SenoVax™, a dendritic cell-based vaccine designed to target and eliminate senescent cells. Preclinical studies have demonstrated its potential to transform the tumor microenvironment by clearing these cells, which are associated with aging and disease progression. Furthermore, in animal models of multiple solid tumor cancers (lung, breast, glioma, pancreatic), SenoVax™ induced significant tumor regression by enhancing immune responses, underscoring its promise as a therapeutic solution for both cancer treatment and longevity research.

The company’s StemCell Revivify™, a set of personalized young and immortal progenitor and mesenchymal stem cells have shown an ability to achieve dramatic recovery of failing organs in multiple animal models. Proprietary iPSC-based stem cell therapies have been developed to provide scalable, practical, and economical solutions.

“We are thrilled to showcase our recent progress and share our vision for tackling the diseases of aging as well as the aging itself,” said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio. “At Immorta Bio, we believe that combining cutting-edge science with a deep understanding of the biology of aging can transform how we address major medical challenges. The Biotech Showcase offers an invaluable platform to engage with innovators, collaborators, and investors while we highlight how our breakthroughs in longevity science are paving the way for healthier, longer lives.”

To learn more about the event, please visit https://informaconnect.com/biotech-showcase/. To schedule a one-on-one with Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, during the event, please email kbash@immortabio.com

About Immorta Bio
Immorta Bio Inc. is a scientific longevity company developing personalized cellular therapeutics focused on Treating Diseases of Aging and Treating Aging as a Disease™. We are advancing longevity medicine by harnessing patient-derived rejuvenated stem cells and enhanced immune cells, restoring the body’s natural ability to combat cancers and age-related diseases. Our mission is to address the root causes of aging and bring resilience and vitality back to you.

To learn more about Immorta Bio’s research initiatives, visit immortabio.comLinkedIn and X.

Media Contact

David Schull  
Russo Partners
858-717-2310
388575@email4pr.com

Kate Bash
Chief Commercial Officer
Immorta Bio
388575@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/immorta-bio-to-present-new-data-on-senovax-and-stemcell-revivify-at-biotech-showcase-2025-302347953.html

SOURCE Immorta Bio Inc.

Continue Reading

Technology

Breaking Stereotypes: New 3Fun Survey Reveals Media’s Missteps in Polyamory Representation

Published

on

By

NEW YORK, Jan. 10, 2025 /PRNewswire/ — Despite growing visibility, only 11% of polyamorous individuals feel media portrayals align with their real-life experiences, according to a new survey by 3Fun, the leading dating app for open-minded singles and partners seeking like-minded connections. The survey, conducted among 1,312 3Fun users, highlights how media misrepresentation shapes public perceptions, reinforces stereotypes, and impacts user expectations on dating platforms like 3Fun.

Key Findings from the 3Fun Survey:

Limited Representation: Nearly 40% of respondents said they rarely see polyamorous relationships in mainstream media, while 17% reported never seeing them at all.Social Media Influence: Platforms like Instagram and TikTok are driving perceptions of polyamory for 40% of users, far surpassing traditional media like TV and film (10%).Accuracy Issues: Only 11% of respondents described media portrayals as “very accurate,” while 52% rated them as “rarely accurate” or “completely inaccurate.”Mixed Progress: While 39% believe portrayals have improved, 38% said they’ve noticed no change at all.Normalization vs. Stereotypes: Social media is a double-edged sword—40% think it normalizes polyamory, but 34% believe it reinforces harmful stereotypes.Global vs. Local Media: Over 21% noted global media tends to be more open-minded about polyamory than local outlets, which are often conservative or avoid the topic altogether.

“The data from this survey shows how far we still have to go in achieving authentic representation of polyamory in media and pop culture,” said Max Ma, Founder and CEO of 3Fun. “These portrayals don’t just shape public opinion—they directly influence how our users feel about their relationships and their ability to live openly. At 3Fun, we’re dedicated to creating a supportive community where everyone can explore their desires without fear of judgment.”

The Real Impact of Misrepresentation

Nearly half of respondents (47%) identified cultural and societal norms as the biggest barriers to societal acceptance of polyamory—more significant than concerns about media portrayal or visibility. However, respondents emphasized that better representation would lead to:

Easier conversations about polyamory (32%)Improved understanding within their social circles (21%)

Gigi Engle, certified sex and relationship psychotherapist and 3Fun’s resident intimacy expert, echoed this sentiment: “Representation matters. Media has the power to normalize relationships and dismantle stereotypes, but only when done thoughtfully. This survey shows a clear need for creators to approach polyamory with authenticity and care.”

Creating a World Where Love Knows No Limits

The findings highlight the role platforms like 3Fun play in bridging the gap between perception and reality. With over 10 million downloads and 3 million verified active users worldwide, 3Fun provides a safe, inclusive space for polyamorous individuals and couples to connect, explore, and thrive.

Join us in building a community where love is celebrated in all its forms. Download 3Fun today and discover a world where love knows no limits.

For more information, visit www.go3fun.co.

About 3Fun:

3Fun, with over 10 million downloads and 3 million verified active users worldwide, is the leading dating app for open-minded singles and partners to meet like-minded people. The platform provides a safe and inclusive space for users to explore ethical open relationships and polyamory lifestyles, fostering community and connection without judgment. Learn more at www.go3fun.co.

Media Contact:
Britni Ackrivo
backrivo@gregoryfca.com
484-504-9920

View original content:https://www.prnewswire.com/news-releases/breaking-stereotypes-new-3fun-survey-reveals-medias-missteps-in-polyamory-representation-302347759.html

SOURCE 3Fun

Continue Reading

Technology

Powerfleet to Present at the 27th Annual Needham Growth Conference

Published

on

By

WOODCLIFF LAKE, N.J., Jan. 10, 2025 /PRNewswire/ — Powerfleet, Inc. (Nasdaq: AIOT) today announced that management is scheduled to present at the 27th Annual Needham Growth Conference on Tuesday, January 14th at 4:30pmET and meet with investors to discuss how Powerfleet is enacting meaningful business change through effective data insights for its customers and underpinning their digital transformations.  

The link to the live webcast of the Company’s presentation will be available by visiting Powerfleets website at https://ir.powerfleet.com/events-presentations/events.

ABOUT POWERFLEET
Powerfleet (Nasdaq: AIOT; JSE: PWR) is a global leader in the artificial intelligence of things (AIoT) software-as-a-service (SaaS) mobile asset industry. With more than 30 years of experience, Powerfleet unifies business operations through the ingestion, harmonization, and integration of data, irrespective of source, and delivers actionable insights to help companies save lives, time, and money. Powerfleet’s ethos transcends our data ecosystem and commitment to innovation; our people-centric approach empowers our customers to realize impactful and sustained business improvement. The company is headquartered in New Jersey, United States, with offices around the globe. Explore more at www.powerfleet.com. Powerfleet has a primary listing on The Nasdaq Global Market and a secondary listing on the Main Board of the Johannesburg Stock Exchange (JSE).

Powerfleet Investor Contacts
Carolyn Capaccio and Jody Burfening
Alliance Advisors IR
AIOTIRTeam@allianceadvisors.com

Powerfleet Media Contact
Jonathan Bates
jonathan.bates@powerfleet.com
+44 7921 242 892

View original content to download multimedia:https://www.prnewswire.com/news-releases/powerfleet-to-present-at-the-27th-annual-needham-growth-conference-302347520.html

SOURCE Powerfleet

Continue Reading

Trending